scholarly journals Drug Liver Injury Induced by Olmesartan Mediated by Autoimmune-Like Mechanism: A Case Report

2020 ◽  
Author(s):  
Manuel de la Torre-Aláez ◽  
Mercedes Iñarrairaegui
Keyword(s):  
Case Report ◽  
Liver Injury ◽  
Drug Exposure ◽  
Interesting Case ◽  
Suspected Drug ◽  
Drug Induced ◽  
Drug Induced Liver Injury ◽  
Difficult Diagnosis ◽  
Histological Confirmation ◽  
The Relationship

Autoimmune hepatitis (AIH) was the first liver disease for which an effective therapeutic intervention was carried out, using prednisolone; its usefulness was demonstrated in several clinical trials. Nevertheless, AIH still remains a difficult diagnosis in some cases, because it is necessary to dismiss other possible diagnoses, and perhaps due to it being a heterogeneous disease. The relationship between drug-induced liver injury (DILI) and AIH is complex and not fully understood. There are three possible scenarios: (1) DILI with a strong immunoallergic component mimicking AIH; (2) AIH mimicking a DILI due to drug exposure and (3) AIH triggered by exposure to an offending drug (drug-induced AIH). Drug-induced AIH is well described and documented for some drugs such as nitrofurantoin and minocycline. Histologically distinguishing DILI from AIH remains a challenge. We present an interesting case report which met serologic criteria and histological confirmation to establish AIH, but discontinuation of a suspected drug resolved hypertransaminasaemia.

scholarly journals A case report of a drug‐induced liver injury (DILI) caused by multiple antidepressants with causality established by the updated Roussel Uclaf causality assessment method (RUCAM) and in vitro testing

2020 ◽  
Vol 8 (12) ◽  
pp. 3105-3109
Author(s):  
Miguel González‐Muñoz ◽  
Jaime Monserrat Villatoro ◽  
Eva Marín‐Serrano ◽  
Stefan Stewart ◽  
Belén Bardón Rivera ◽  
...  
Keyword(s):  
Case Report ◽  
Liver Injury ◽  
Causality Assessment ◽  
Assessment Method ◽  
In Vitro Testing ◽  
Drug Induced ◽  
Drug Induced Liver Injury

A Case Report of Rifampin Alone Drug Induced Liver Injury (DILI)

2018 ◽  
Vol 113 (Supplement) ◽  
pp. S1271
Author(s):  
Ashina D. Singh ◽  
Scott A. Manski ◽  
Nathalie H. Urrunaga
Keyword(s):  
Case Report ◽  
Liver Injury ◽  
Drug Induced ◽  
Drug Induced Liver Injury

2341 An Interesting Case of Drug-Induced Liver Injury Related to Khat

2019 ◽  
Vol 114 (1) ◽  
pp. S1305-S1306
Author(s):  
Daniel J. Waintraub ◽  
Kaveh Zivari ◽  
Richard M. Fazio ◽  
Jonathan Weinberger ◽  
Rabin Rahmani ◽  
...  
Keyword(s):  
Liver Injury ◽  
Interesting Case ◽  
Drug Induced ◽  
Drug Induced Liver Injury

scholarly journals Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery

PLoS ONE ◽  
2017 ◽  
Vol 12 (12) ◽  
pp. e0189436 ◽  
Author(s):  
Valentina Peta ◽  
Chantal Tse ◽  
Hugo Perazzo ◽  
Mona Munteanu ◽  
Yen Ngo ◽  
...  
Keyword(s):  
Liver Injury ◽  
Apolipoprotein A1 ◽  
Suspected Drug ◽  
Drug Induced ◽  
Drug Induced Liver Injury

scholarly journals Advances in Engineered Liver Models for Investigating Drug-Induced Liver Injury

2016 ◽  
Vol 2016 ◽  
pp. 1-20 ◽  
Author(s):  
Christine Lin ◽  
Salman R. Khetani
Keyword(s):  
Liver Injury ◽  
Human Liver ◽  
Animal Studies ◽  
Drug Exposure ◽  
Induced Pluripotent Stem Cell ◽  
Cell Types ◽  
Rapid Decline ◽  
Cellular Mechanisms ◽  
Drug Induced ◽  
Drug Induced Liver Injury

Drug-induced liver injury (DILI) is a major cause of drug attrition. Testing drugs on human liver models is essential to mitigate the risk of clinical DILI since animal studies do not always suffice due to species-specific differences in liver pathways. While primary human hepatocytes (PHHs) can be cultured on extracellular matrix proteins, a rapid decline in functions leads to low sensitivity (<50%) in DILI prediction. Semiconductor-driven engineering tools now allow precise control over the hepatocyte microenvironment to enhance and stabilize phenotypic functions. The latest platforms coculture PHHs with stromal cells to achieve hepatic stability and enable crosstalk between the various liver cell types towards capturing complex cellular mechanisms in DILI. The recent introduction of induced pluripotent stem cell-derived human hepatocyte-like cells can potentially allow a better understanding of interindividual differences in idiosyncratic DILI. Liver models are also being coupled to other tissue models via microfluidic perfusion to study the intertissue crosstalk upon drug exposure as in a live organism. Here, we review the major advances being made in the engineering of liver models and readouts as they pertain to DILI investigations. We anticipate that engineered human liver models will reduce drug attrition, animal usage, and cases of DILI in humans.

Sign in / Sign up

Export Citation Format

Share Document